Production facilities

Steadily growing demand for our product requires continuous efforts to maximise production volume.

Production takes place in the group’s manufacturing facilities at Sandefjord in Norway and in Kalundborg, Denmark. The new state-of-the-art plant in Kalundborg became operational in the third quarter of 2009. This plant is designed to give the group another 1,200 tonnes in annual production capacity. This will increase the ability to serve rapidly growing global markets.

Optimisation in Sandefjord

The plants use a unique and complex manufacturing process to produce the highly purified omega-3 derived pharmaceutical product. There are about 120 highly skilled, specialised personnel, engineers, laboratory technicians and process operators employed at the manufacturing plant. Some NOK 800 million have been invested in the Sandefjord plant since 2004 in response to growing demand. This has increased production capacity by 300 per cent.

New capacity in Kalundborg

The first commercial shipment from the new manufacturing plant is expected during the first quarter of 2010, following achieved regulatory approvals. The Kalundborg facility became operational in third quarter 2009.

Construction work started in October 2007, and building and assembly have progressed in the same streamlined manner as in the plant itself. The production of intermediary products started in the third quarter and the plant was officially opened 1 October 2009.

The new facility uses the optimised technology already deployed in the Sandefjord plant.
Kalundborg is ideally located in Denmark’s pharmaceutical development cluster. The infrastructure is excellent for manufacturing pharmaceutical products, and local authorities have demonstrated a constructive and positive attitude during preperations and meeting the group’s needs. The recruitment process has also confirmed Pronova BioPharma’s ability to attract highly qualified personnel from the region.

Pronova BioPharma currently has some 110 employees in Kalundborg. Since the technology is duplicated from the Sandefjord plant, the personnel have undergone extensive training programs in Norway.

With an annual production capacity of 1,200 tonnes, the Kalundborg plant will enable Pronova BioPharma to continue its fast growth. Further expansion of the new facility will also be possible when required. The design is modular , with the capacity for two additional modules of 600 tonnes production capacity.